Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment

Daniela Rizzo, Antonio Ruggiero*, Maurizio Martini, Valentina Rizzo, Palma Maurizi, Riccardo Riccardi

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

36 Citazioni (Scopus)


High-grade gliomas are the main cause of death in children with brain tumours. Despite recent advances in cancer therapy, their prognosis remains poor and the treatment is still challenging. To date, surgery followed by radiotherapy and temozolomide is the standard therapy. However, increasing knowledge of glioma biology is starting to impact drug development towards targeted therapies. The identification of agents directed against molecular targets aims at going beyond the traditional therapeutic approach in order to develop a personalized therapy and improve the outcome of pediatric high-grade gliomas. In this paper, we critically review the literature regarding the genetic abnormalities implicated in the pathogenesis of pediatric malignant gliomas and the current development of molecularly targeted therapies. In particular, we analyse the impact of molecular biology on the prognosis and treatment of pediatric high-grade glioma, comparing it to that of adult gliomas.
Lingua originaleEnglish
pagine (da-a)1-10
Numero di pagine10
RivistaBioMed Research International
Stato di pubblicazionePubblicato - 2015


  • Adolescent
  • Adult
  • Biochemistry, Genetics and Molecular Biology (all)
  • Biomarkers, Tumor
  • Brain Neoplasms
  • Child
  • Child, Preschool
  • Female
  • Glioma
  • Humans
  • Immunology and Microbiology (all)
  • Infant
  • Male
  • Neoplasm Proteins


Entra nei temi di ricerca di 'Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment'. Insieme formano una fingerprint unica.

Cita questo